Earnings Call Summary | GETINGE AB(GNGBF.US) Q2 2024 Earnings Conference
Earnings Call Summary | GETINGE AB(GNGBF.US) Q2 2024 Earnings Conference
Gross profit increased by SEK837 million to SEK4,151 million, with adjusted gross margin improving across all business areas.The following is a summary of the Getinge AB (GNGBF) Q2 2024 Earnings Call Transcript:
以下为Getinge Ab(GNGBF)2024财年第二季度业绩会摘要：
Financial Performance:
金融业绩：
Getinge reported a 15.7% increase in net sales and 14.4% growth in order intake in Q2 2024.
Adjusted EBITDA margin improved by 4.9 percentage points year-on-year.
Gross profit increased by SEK837 million to SEK4,151 million, with adjusted gross margin improving across all business areas.
盖世报告2024年第二季度净销售额增长15.7％，订单增长14.4％。
调整后的EBITDA边际率同比提高4.9个百分点。
毛利润增加了8369百万瑞典克朗至41510百万瑞典克朗，调整后各业务领域毛利率均有所提高。
Business Progress:
业务进展：
Launched Poladus 150, an advanced low-temperature sterilizer, and received 510(k) clearance and EU MDR approval for new products.
Presented an updated earnings per share target with an average growth of over 12% for 2024-2028 during the Capital Market Update.
Advanced the quality improvement for products like Cardiosave and Cardiohelp and made progress towards sustainable productivity improvements.
推出了先进的低温灭菌器Poladus 150，并获得了新产品的510(k)和欧盟MDR批准。
在资本市场更新中提出了更新后的每股收益目标，2024-2028年平均增长率超过12％。
推进Cardiosave和Cardiohelp等产品的质量改进，并取得可持续生产力改进方面的进展。
Opportunities:
机会：
The company continues to see good market opportunities in Asia Pacific, expecting strong demand for healthcare.
Recent acquisitions are expected to contribute to 3-5 percentage points of growth, complemented by 2-5% expected organic net sales growth.
公司在亚太地区仍看到良好的市场机会，预计医疗保健需求强劲。
预计最近的收购将为增长贡献3-5个百分点，同时伴随预期净有机销售增长率为2-5％。
Risks:
风险：
Quality-related challenges in Acute Care Therapies remain a priority.
Regulatory hurdles with pending CE mark approvals for new ECMO packaging.
急性护理治疗方面的质量相关挑战仍然是重点。
新ECMO包装的CE标准批准存在监管障碍。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息，请参阅IR网站。本文只是为投资者提供参考，没有任何指导或推荐建议。
